The synthetic cannabinoid WIN 55,212-2 attenuates cognitive and motor deficits and reduces amyloid load in 5XFAD Alzheimer mice
This study highlights the therapeutic potential of WIN 55,212-2 in AD by ameliorating cognitive and motor deficits and reducing neuropathology. These findings support a cannabinoid-based therapy as a promising strategy for AD treatment, with WIN 55,212-2 emerging as a potential candidate.
Authors
- Yvonne Bouter (ORCID: https://orcid.org/0009-0002-3893-598X)
- Johanna E L Möller
- Daniel Günther (ORCID: https://orcid.org/0000-0001-8268-6998)
- Alexander E. Stover
- F. Schmitt (ORCID: https://orcid.org/0000-0002-6878-6084)
Institutions
- University of Göttingen (DE)
Publication Details
- Journal
- Pharmacology Biochemistry and Behavior
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1016/j.pbb.2024.173944
- Citations
- 4
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 1.79